Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 7:15:1513900.
doi: 10.3389/fmicb.2024.1513900. eCollection 2024.

Editorial: New therapeutic strategies against carbapenem-resistant gram-negative bacteria

Maria Teresa Mascellino  1 , Alessandra Oliva  1 , Silpak Biswas  2 , Giancarlo Ceccarelli  1
Affiliations
Editorial

Editorial: New therapeutic strategies against carbapenem-resistant gram-negative bacteria

Maria Teresa Mascellino et al. Front Microbiol. .
No abstract available

Keywords: antibiotic resistance; antibiotics; bacterial pathogen; carbapenem; carbapenem resistance; β-lactamase.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Possible solutions to overcome bacterial carbapenem-resistance. From Mascellino et al. (2024). Source BioRender.com.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic New therapeutic strategies against carbapenem-resistant gram-negative bacteria

References

    1. Gaibani P., Giani T., Bovo F., Lombardo D., Amadesi S., Lazzarotto T., et al. . (2022). Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in gram-negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics 11:628. 10.3390/antibiotics11050628 - DOI - PMC - PubMed
    1. Li Z. H., Wang J., Xu J. P., Wang J., Yang X. (2023). Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. Mil. Med. Res. 10:12. 10.1186/s40779-023-00447-X - DOI - PMC - PubMed
    1. Mascellino M.T., Biswas S., Oliva A. (2024). Editorial: Enterobacteriaceae antimicroibial agents and resistance: relation with the therapeutic approach volume II. Front. Cell. Infect. Microbiol. 14:1356413. 10.3389/fcimb.2024.1356413 - DOI - PMC - PubMed
    1. Oliva A., Bianchi A., Russo A., Ceccarelli G., Cancelli F., Aloj F., et al. . (2021). Effect of N-acetylcysteine administration on 30-day mortality in critically ill patients with septic shock caused by carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii: a retrospective case-control study. Antibiotics 10:271. 10.3390/antibiotics10030271 - DOI - PMC - PubMed
    1. Qin J., Wu N., Bao J., Shi X., Ou H., Ye S., et al. . (2021). Heterogeneous Klebsiella pneumoniae co-infections complicate personalized bacteriophage therapy. Front. Cell. Infect. Microbiol. 10:608402. 10.3389/fcimb.2020.608402 - DOI - PMC - PubMed

Publication types

LinkOut - more resources